Leap Therapeutics (LPTX)

• Market cap: $15.3M
• 1 day: 2.33%
• 5 days: -8.34%
• 1 month: -20.57%
• 3 months: -86.71%
• 6 months: -86.71%
• Year to date: -87.57%
• 1 year: -81.81%
• 5 years: -96.92%
• 10 years: -99.49%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Employees: 54

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

150% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 6

122% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 9

46% more capital invested

Capital invested by funds: $38.1M [Q3] → $55.6M (+$17.5M) [Q4]

19% more funds holding

Funds holding: 48 [Q3] → 57 (+9) [Q4]

11.72% more ownership

Funds ownership: 38.73% [Q3] → 50.46% (+11.72%) [Q4]

70% less call options, than puts

Call options by funds: $43K | Put options by funds: $142K